Applikon to buy HaloteC’s biotech portfolio
Bioreactor systems vendor Applikon Biotechnology has arranged to acquire the biotech portfolio of Dutch instruments and software provider HaloteC Instruments.
Applikon CEO Arthur Oudshoorn said the company plans to use the HaloteC technology to augment its existing its bioreactor software offerings.
“Organisations are looking for software solutions to allow parallel processing of bioreactor systems and to process the large amount of data generated by these processes,” he said.
Oudshoorn added that the investment forms part of Applikon’s efforts to be able to provide an advanced data centre for biotech processes.
Terms of the transaction were not disclosed.
Applikon Biotechnology is headquartered in the Netherlands and in Belgium. In Australia and New Zealand, the company provides its products through its dedicated agent Enztech in New South Wales.
No clear link between paracetamol in pregnancy and autism/ADHD
Existing evidence does not clearly link paracetamol (acetaminophen) use during pregnancy with...
Light at night can increase heart disease risk
Being exposed to bright light at night can significantly increase your chances of developing...
Scientists find new driver of ovarian cancer spread
A cell surface receptor known as F2R could serve as both a diagnostic marker for ovarian cancer...
